Jan 24, 2020 7:05am EST

IMV to Host Key Opinion Leader Symposium on Role of Survivin in Cancer Biology and Potential of DPX-Survivac

Dec 08, 2019 12:05pm EST

Updated Clinical Data from Phase 2 SPiReL Study Evaluating DPX-Survivac as a Combination Therapy in r/r DLBCL Presented at 61st American Society of Hematology (ASH) Annual Meeting

Nov 27, 2019 7:05am EST

IMV to Participate at Two Upcoming Investor Conferences

Nov 08, 2019 7:05am EST

IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update

Nov 06, 2019 9:01am EST

Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting

Nov 05, 2019 8:01am EST

IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting

Oct 30, 2019 7:05am EDT

IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer

Oct 29, 2019 7:05am EDT

IMV Inc. to Announce Third Quarter 2019 Results and Host a Conference Call and Webcast on November 8, 2019

Oct 16, 2019 10:01am EDT

/ C O R R E C T I O N From Source – IMV Inc /

Oct 11, 2019 7:05am EDT

IMV Inc. to Present at Upcoming Investor Conference